Greenland Mines (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508, covering gene therapy technology exclusively licensed by the company’s Biotech Division. The patent pertains to the expression of the human Klotho protein for treating neuromuscular diseases, including amyotrophic lateral sclerosis (ALS). This development strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems.
The patent further supports development of the company’s KLTO-202 program, which is targeting ALS and other neuromuscular disorders. ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to muscle weakness and eventual paralysis. There is currently no cure, and available treatments only modestly slow progression. The Klotho protein has been studied for its potential neuroprotective effects, and its expression through gene therapy could offer a novel approach to treating such conditions.
Greenland Mines operates through two divisions: Mining and Biotech. The mining division focuses on exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of a previously announced transaction, the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland. The biotech division includes the Klotho platform, with KLTO-202 as the primary indication for ALS. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The granted patent adds to Greenland Mines’ intellectual property portfolio, which is crucial for advancing its gene therapy platform. For more details on the patent, visit the full press release at https://nnw.fm/PVbbH. The company also maintains a newsroom for the latest updates at https://ibn.fm/GRML.
Forward-looking statements in this article involve risks and uncertainties, including those detailed in the company’s filings with the SEC. Greenland Mines undertakes no duty to update this information unless required by law.
